| Target Price | HK$8.67 |
| Price | HK$7.32 |
| Potential |
18.52%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target China Shineway Pharmaceutica 2027 .
The average China Shineway Pharmaceutica target price is HK$8.67.
This is
18.52%
register free of charge
HK$8.93
22.01%
register free of charge
HK$8.59
17.36%
register free of charge
|
|
| A rating was issued by 9 analysts: 0 Analysts recommend China Shineway Pharmaceutica to buy, 3 to hold and 6 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the China Shineway Pharmaceutica stock has an average upside potential 2027 of
18.52%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion HK$ | 3.67 | 2.80 |
| 17.01% | 23.74% | |
| EBITDA Margin | 29.54% | 34.68% |
| 3.06% | 17.40% | |
| Net Margin | 30.30% | 35.28% |
| 36.26% | 16.45% |
3 Analysts have issued a sales forecast China Shineway Pharmaceutica 2026 . The average China Shineway Pharmaceutica sales estimate is
This results in the following potential growth metrics:
3 China Shineway Pharmaceutica Analysts have issued a net profit forecast 2026. The average China Shineway Pharmaceutica net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | 1.47 | 1.19 |
| 13.08% | 19.05% | |
| P/E | 6.13 | |
| EV/Sales | negative |
3 Analysts have issued a China Shineway Pharmaceutica forecast for earnings per share. The average China Shineway Pharmaceutica EPS is
This results in the following potential growth metrics and future valuations:
China Shineway Pharmaceutica...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


